Applying Statistical Models to Health Outcomes

For Australian Patients with Bronchiectasis

Pitchaya Kingkam

FACULTY OF SCIENCE UNIVERSITY OF TECHNOLOGY SYDNEY

A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy April 2021

CERTIFICATE OF ORIGINAL AUTHORSHIP

I, [Pitchaya Kingkam] declare that this thesis, is submitted in fulfilment of the requirements for the award of doctoral degree, in the School of Mathematical and Physical Sciences at the University of Technology Sydney.

This thesis is wholly my own work unless otherwise reference or acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

This document has not been submitted for qualifications at any other academic institution.

This research is supported by the Australian Government Research Training Program.

Production Note: Signature of Student: Signature removed prior to publication. Date: 30 April 2021

ACKNOWLEDGEMENT

First of all, I would like to express my gratitude and appreciation to my supervisors, Professor James Brown, Associate Professor Stephen Woodcock and Associate Professor Lucy Morgan. My priceless journey started when Professor James Brown and Dr. Stephen Woodcock accepted me to work on this project. I am extremely thankful for all supports, guidance and insightful comments throughout the development of this thesis. Without their help and kindness, I would not have survived from unexpected situations. Indeed, I do appreciate their excellent supervision, motivation and valuable support. For years, I have learned a lot for being a good researcher. This is a precious time and wonderful experience in my life.

I would like to express my very great appreciation to Professor Tony Moon. He is such a guardian angel for me and Thai students. I am grateful to meet him in Sydney. I will never forget his encourage and kindness for the rest of my life.

I would like to express my special thanks to Doctor Lucy Morgan, Concord Hospital, and Lung Foundation Australia for helping me to understand chronic lung disease (especially bronchiectasis) and how statistics can help us all understand the patient journey.

I would also like to express my deep gratitude to my family, friends and all Thai government staffs for their caring and great supports when I faced difficult situations.

Finally, I would like to dedicate this thesis to my deceased father, who passed away during my study. His love gave me forces to make this project.

ABSTRACT

Bronchiectasis is a common disease caused by chronic infection in the small airways of the lungs. Patients often carry a heavy burden of symptoms. Unfortunately, little is known about the impact of bronchiectasis on Australians or on our healthcare system. For many years, bronchiectasis was considered as another Chronic Obstructive Pulmonary Disease and was bundled (for costing purposes) with COPD or other pulmonary infections, without recognition that the condition was associated with significant, particular clinical features that required longer and more complex admissions to hospital than COPD. Prior to July 2018, there was no disease specific code within the system that allocates hospital funding and consequently, episodes of care for patients with bronchiectasis were assigned into other respiratory illness in the AR-DRG system. This misallocation is likely to have affected hospital funding which is calculated based on ALOS associated with the AR-DRG group of diseases. The main purpose of this thesis was to explore the factors contributing to the length of stay and hospital readmission for patients with bronchiectasis in Australia in three parts;

i) An evaluation of the effect of a specific AR-DRG on funding of length of hospital stay for bronchiectasis patients and a comparison of the actual length of stay in hospital (LOS) with the average length of stay (ALOS) based on the assigned AR-DRG. We found that the AR-DRG system consistently underestimated the LOS and costs for acute hospital admissions due to bronchiectasis.

ii) An investigation of the effect of seasonality of presentation and patient characteristics (sex, age, smoking status, ABR registry status) on hospital LOS and ALOS. The cohort in this study included 299 patients who were diagnosed as bronchiectasis with 505 admissions of >24 hours to Concord Hospital, NSW between July 2011-June 2018. The results were showing significance (p < 0.05) between the non ABR-registry and the response lnALOS. This implied that bronchiectasis patients who participated with ABR- registry tend to have length of stay in hospital shorter than patients who did not register in the ABR.

iii) An analysis of the time between episodes of care of bronchiectasis patients using longitudinal data analysis and multilevel models. Bronchiectasis patients who were smokers and hospital LOS, were statistically significant risk factors for readmission. Hospital LOS was negatively correlated with time to readmission suggesting that longer stays in hospital can reduce readmission risk. In addition, patients who were smokers had a significantly higher readmission rate than patients who were not smokers.

TABLE OF CONTENTS

CHAPTER1- Introduction

1.1 Project overview and motivation	.1
1.2 Project Aims and Objective.	2
1.3 Layout of the Thesis	.3

CHAPTER2-Literature Review

2.1 Bronchiectasis	4
2.1.1 Causes of bronchiectasis	5
2.1.2 Symptoms of bronchiectasis	6
2.1.3 Diagnosis	8
2.1.4 An overview of prevalence of bronchiectasis	
2.1.5 Bronchiectasis treatments.	11
2.1.6 The Australian Refined Diagnosis Related Groups	14
2.1.7 Length of hospital stay	
2.2 Statistical models	21
2.2.1 Linear Regression models	21
2.2.2 Multilevel models	23
2.2.3 Survival Analysis Models	25
2.3 Conclusion	

CHAPTER3-The Data

3.1 Background to the data	
3.1.1 Definitions	
3.1.2 Australian Admitted Patient Care during 2017-18	
3.1.3 Bronchiectasis hospitalizations in Australia	
3.1.4 Hospital Performance Indicator: Average length of stay	
3.2 The Australian Bronchiectasis registry (ABR)	
3.3 Bronchiectasis patients in Concord Hospital 2011-2018	
3.4 Conclusion.	41

CHAPTER4- Models for Analyzing Patient Length of Stay in Hospital

4.1 Average length of stay in hospital (ALOS)	42
4.2 Bronchiectasis in the AR-DRG classification System	43
4.2.1 Bronchiectasis length of stay in Concord Hospital (2011-2018)	46
4.3 Bronchiectasis Patient Characteristics	49
4.4 Model Assumptions	52
4.5 Results	54
4.5.1 Regression models for analyzing the relationship between LOS and ALOS	54
4.5.2Two-Level hierarchical models for investigating the relationship between LOS	S and
ALOS	59
4.5.3 Factors affecting bronchiectasis hospital length of stay	63
4.6 Conclusion	72

CHAPTER 5-Models for analyzing time to readmission among bronchiectasis patients

5.1 Introduction to analysis	73
5.2 Preparing the data	74
5.3 Model Assumptions.	76
5.4 Modelling the time to readmission among bronchiectasis patients in Concord	1 Hospital78
5.5 Results	
5.5.1 Multilevel Logistic Model for time to hospital readmission	80
5.5.2Multilevel Logistic Model for investigating factors affecting to hospital	
Readmission.	
5.6 Conclusion	94

CHAPTER 6-Conclusion and Discussion

6.1 Summary of thesis contribution	96
6.2 Summary of the results	97
6.3Limitations	101
6.4 Further Works	102
REFERENCES	104

LIST OF TABLES

Table 2.1 Symptoms of bronchiectasis severity
Table 3.1 Separations, by principal diagnosis, between public and private hospitals 2017-18
Table 3.2 Average length of stay (ALOS), publics and private hospitals from 2013-14 to
2017-18
Table 3.3 Percent of bronchiectasis patients in Concord Hospital by gender, July 2011-June
2018
Table 3.4 Number of episode of bronchiectasis patients in Concord Hospital by age-groups,
July 2011- June 2018
Table 3.5 Bronchiectasis hospital admissions were categorized by season in Concord
Hospital during July 2011- June 2018
Table 4.1 The most common assignment for bronchiectasis patients, Concord Hospital 2011-
2018
Table 4.2 Bronchiectasis patient length of stay in Concord Hospital, Sydney July 2011-June
2018
Table 4.3 Comparison of ALOS of bronchiectasis patients (E77) with the two most common
disease groups (E62A, E65A) into which bronchiectasis patients were likely to have been
coded (2018-19)
Table 4.4 Comparison of age groups of bronchiectasis patients during July2011- June2018 in
Concord Hospital
Table 4.5 Models Summary
Table 4.6 Parameter Estimates 55
Table 4.7 Analysis of variance table
Table 4.8 single-level model with one predictor variable (lnALOS)
Table 4.9.1 Parameter estimates of the empty multilevel model1 (null model)61
Table 4.9.2 Parameter estimates of the empty multilevel model2 (null model)
Table 4.10 Two-level model with one predictor variable (lnALOS)
Table 4.11 Parameter estimates by adding age groups as a predictor of a two-level model
1
Table 4.12 Parameter estimates by adding age groups as a predictor of a two-level model
Table 4 13 Parameter estimates by including gender into a two-level model 1 66
Table 4.14 Parameter estimates by including gender into a two-level model 2 66
Table 4.15 Parameter estimates by including smoking status as a predictor of a two-level
model 1

Table 4.16 Parameter estimates by including smoking status as a predictor of a two-level
model 167
Table 4.17 Parameter estimates by including non ABR-registry status as a predictor of a two-
level model 1
Table 4.18 Parameter estimates by including non ABR-registry status as a predictor of a two-
level model 2
Table 4.19 Parameter estimates by including non ABR-registry status and InALOS as
predictors of a two-level
Table 4.20 Number of bronchiectasis patient admissions in Concord Hospital during July
2011- June 2018
Table 4.21 Parameter estimates by including season as a predictor of a two-level model171
Table 4.22 Parameter estimates by including season as a predictor of a two-level model271
Table 5.1 Parameter estimates for the multilevel logistic model for binary response of
bronchiectasis patient's readmission into Concord Hospital during 16 weeks since discharge
date
Table 5.2 Parameter estimates for the multilevel logistic model for binary response of
bronchiectasis patient's readmission into Concord Hospital during 16 weeks since discharge
date
Table 5.3 Parameter estimates of model 5.3 by using MLwiN
Table 5.4 Analysis of Deviance from Table 5.2. 85
Table 5.5 Estimated Effects of Gender on the Probability of Readmission and Time to
Readmission
Table 5.6 Estimated Effects of Age-groups on the Probability of Readmission and Time to
Readmission
Table 5.7 Estimated Effects of Smoking-status on the Probability of Readmission and Time
to Readmission
Table 5.8 Estimated Effects of ABR-Registry on the Probability of Readmission and Time
to Readmission
Table 5.9 Estimated Effects of Seasonality on the Probability of Readmission and Time to
Readmission
Table 5.10 Estimated Effects of hospital LOS on the Probability of Readmission and Time
to Readmission
Table 5.11 Parameter estimates of Model 5.6 (model with two significant factors: smoker,
lnLOS)
Table 5.12 Probability of bronchiectasis readmission within 13 and 16 weeks
Table 6.1 Probability of bronchiectasis readmission within 16 weeks 100

LIST OF FIGURES

Figure 1 Computed Tomography of bronchiectasis Figure 2 A cycle of infection and inflammation of bronchiectasis
Figure 3 Chest Physiotherapy and Postural Drainage
Figure 4 Inlier bound (ALOS) calculation
Figure 5 Residuals vs Fitted plots
Figure 6 Quantile-Quantile plot. 22
Figure 7 A two- level hierarchical structure of patients in hospitals2
Figure 8 Survival curves after chemotherapy for solid tumors stratified by tumor response
Figure 9 Rate of hospitalizations of bronchiectasis from 2006-07 to 2016-18
Figure 10 Differences by gender on bronchiectasis patients in Concord Hospital during July
2011- June 2018
Figure 11 The proportion of age groups of bronchiectasis patients in Concord Hospital, Jul
2011-June 2018
Figure 12 Proportion of bronchiectasis patients in Concord Hospital, by smoking status, Jul
2011- June 2018
Figure 13 Season of admissions of bronchiectasis patients in Concord Hospital during July
2011-June 2018
Figure 14 Groups of 8(AR- DRGs) for 299 bronchiectasis patients in Concord Hospital
July 2011-June 2018
Figure 15 LOS histogram with a normal distribution curve superimposed for bronchiectasi
patients, Concord Hospital, July 2011- June20184'
Figure 16 ALOS with a normal distribution curve for bronchiectasis patients, Concord
Hospital, July 2011-June 20184'
Figure 17 The boxplots of the actual length of stay (LOS) and the average length of stay
(ALOS) in hospital of bronchiectasis patients in Concord Hospital during July 2011- June
2018
Figure 18 LOS of bronchiectasis patients by gender, Concord Hospital during July 2011
June 2018
Figure 19 Boxplots of LOS by Age groups of bronchiectasis patients in Concord Hospita
(July 2011-June 2018)
Figure 20 LOS of Bronchiectasis patients by smoking status, Concord Hospital, July 2011
June 2018
Figure 21 Bronchiectasis patients by registry status, Concord Hospital, July 2011- June 2018
Figure 22 Residuals VS fitted Values for simple linear regression model50

Figure 23 Residuals VS fitted values for log-log linear regression model57
Figure 24 Q-Q plot for simple linear regression model
Figure 25 Q-Q plot for log- log linear regression model
Figure 26 The relationship between the LOS and ALOS of bronchiectasis patients (Concord
Hospital July2011- June 2018) by the log transformed model
Figure 27 Histogram of time between episodes of care in months (Concord Hospital
bronchiectasis patients in the period July 2011- June 2018)75
Figure 28 Boxplots shown distributions between censored group (No- readmission) and
return group (readmission)of bronchiectasis patients to Concord Hospital during July 2011-
June201875
Figure 29 The relationship between ALOS, LOS, patient characteristics and readmission77
Figure 30 Hazard for Time to Readmission within 16 weeks
Figure 31The Kaplan-Meier Survival Curve for Time to Readmission 16 weeks
Figure 32 Probability for Time to Readmission within 16 weeks
Figure 33The Kaplan-Meier Survival Curve for Time to Readmission between males and
females within 16 weeks
Figure 34 The Kaplan-Meier Survival Curve for Time to Readmission between aged- groups
within 16 weeks
Figure 35 The Kaplan-Meier Survival Curve for Time to Hospital Readmission of patients'
smoking status within 16 weeks
Figure 36 The Kaplan-Meier Survival Curve for Time to Hospital Readmission of patients'
ABR-registry status within 16 weeks
Figure 37 Kaplan-Meier Survival Curve for Time to Hospital Readmission based on
seasonality within 16 weeks
Figure 38 Probability for Time to Readmission of bronchiectasis patient in Concord Hospital
within 16 weeks by adding the couple significant factors: smoking status and lnLOS (mean of
LOS =11.19)
Figure 39 The relationship between LOS, patient smoking status and readmission95

LIST OF PUBLICATION

KINGKAM, P., VISSER, S., BROWN, J., WOODCOCK, S., BAIRD, T., JACKSON, D. & MORGAN, L. 2017. The argument for a bronchiectasis specific AR-DRG: analysis of hospital discharge data (2012-2016) for patients registered to the Australian Bronchiectasis Registry. *Respirology*, 22, 206-207.